+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Alzheimer’s Disease Therapeutics And Diagnostics Market Set To Grow To $16bn By 2021

10 August 2018
Pharma

Visiongain has launched a new pharma report Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027: Leading Drugs, Pipeline Drugs, Biomarkers, Leading Companies

Alzheimer’s Disease is reported to be the most common form of dementia in developed countries, with a prevalence of about 1% at the age of 65 and over 25% in people older than 85 years of age. Currently, advances in diagnostic technologies remain moderate and the Alzheimer’s Disease biomarker market is still in its infancy. It is expected that several diagnostic tools in the future will offer an accurate assessment of whether an individual has Alzheimer’s Disease, rather than one definitive diagnostic tool.

The lead analyst of the report commented ““The Alzheimer’s disease therapeutics market has been stagnant over the last few years, with many drugs failing late stage clinical trials. The overall AD market has experienced a slow growth in revenues due to the patent expiries of key drugs in major markets. There is a more positive outlook in the diagnostics market with advances in blood-based biomarkers, they are making a huge impact on clinical research of Alzheimer’s drug candidates. The Alzheimer’s Disease market will experience steady growth driven by the rising prevalence of AD and the entry of disease-modifying therapies (DMTs), including the passive immunotherapies, solanezumab, gantenerumab, and BACE inhibitors, verubecestat, which will have significant uptake in major markets”

Leading companies featured in the report include Pfizer, Eisai, Actavis, Lundbeck, Daiichi Sankyo, Novartis, TauRx, vTv Therapeutics, Eli Lilly, Amarantus Biosciences Holdings, Piramal Enterprises, GE Healthcare, Navidea, DiaGenic.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033

The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033

31 May 2023

Read

Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033

The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.

26 May 2023

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033

The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033

24 May 2023

Read

Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033

The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033

23 May 2023

Read